Partnership with Gubra goals to determine and advance a lead long-acting GLP-1 receptor antagonist candidate into IND-enabling research.
US biopharma Amylyx Pharmaceuticals has launched into a collaboration with Danish biotech Gubra to develop a novel long-acting GLP-1 receptor antagonist. The partnership comes as Amylyx seeks to diversify its pipeline following the withdrawal of its FDA-approved ALS treatment earlier this 12 months, prompted by medical trial information indicating a scarcity of efficacy.
The GLP-1 drug class has generated important consideration within the pharmaceutical trade, spurred by the widespread success of diabetes and weight reduction remedies akin to Ozempic and Wegovy. These medicine, which inhibit the GLP-1 receptor, have pushed renewed funding in metabolic illness analysis and growth, and have been closely linked to potential longevity benefits. The Gubra collaboration shouldn’t be Amylyx’s first foray into the GLP-1 house – earlier this 12 months, the corporate acquired a GLP-1 receptor antagonist from Eiger Biopharma for $35.1 million, which is beneath growth as a possible remedy for post-bariatric hypoglycemia.
Via the brand new collaboration, Amylyx goals to capitalize on Gubra’s technological capabilities and observe report of accelerating peptide discovery and growth, and envisions figuring out a lead candidate to advance into Investigational New Drug (IND)-enabling research. As soon as this milestone is achieved, Amylyx retains the choice to spearhead additional growth of the therapeutic candidate.
“The GLP-1 receptor is a well-characterized organic goal and one of many key regulators of the glucose insulin response,” learn a press release attributed to Amylyx’s co-CEOs Joshua Cohen and Justin Klee. “Given the extremely important information avexitide, our first-in-class GLP-1 receptor antagonist, has generated to this point, we’re excited to additional discover this recognized pathway and the potential of including to our pipeline a brand new long-acting GLP-1 receptor antagonist.”
Gubra will obtain upfront and analysis funds and stands to earn over $50 million in growth and commercialization milestones if the venture achieves success. Moreover, the settlement contains provisions for mid-single-digit royalties on world web gross sales.
Established in Denmark in 2008, Gubra brings specialised experience in peptide-based drug discovery and preclinical analysis, with a specific concentrate on metabolic and fibrotic illnesses. The corporate says its drug discovery course of integrates machine studying and AI-driven evaluation, enabling speedy screening of peptide candidates to determine these with probably the most promising therapeutic profiles.
“We’re happy to companion with Amylyx to advance GLP-1 receptor antagonism analysis,” stated Henrik Blou, CEO of Gubra. “This collaboration and growth settlement is an instance of main pharmaceutical corporations partnering with us for our machine learning-based peptide drug discovery platform.”
